EQ 427 snags Series A
EG 427, a developer of pinpoint gene therapy, has secured 12 million euros in Series A funding.
1 March 2021•1 min read
EG 427, a developer of pinpoint gene therapy, has secured 12 million euros in Series A funding.
New AI threats are fueling VC investment in cybersecurity
22 October 2026 · 4 mins read
Inspired Capital holds quick close on $450m for Fund IV
20 October 2026 · 4 mins read
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
DOWNLOAD: Fundraising holds steady in Q3
14 October 2026 · 2 mins read
Why Endeavor Catalyst is betting big on Southeast Asia
8 October 2026 · 4 mins read
Dig's new fund bets on infrastructure built around foundation models
6 October 2026 · 4 mins read
